Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Piscitelli

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Clinical Endocrinology|September 1, 1993
The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study GroupJ Webster, G Piscitelli, A Polli, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|June 1, 1986
Evidence for an inhibition of thyroid hormone effects during chronic treatment with amiodaroneP Beck-Peccoz, A Volpi, A P Maggioni, et al.
Hormone Research|January 1, 1988
Treatment of inappropriate secretion of thyrotropin with somatostatin analog SMS 201-995P Beck-Peccoz, G Medri, G Piscitelli, et al.
Il Giornale Di Chirurgia|November 29, 2017
Laparoscopic sleeve gastrectomy for morbid obesity: role of intraluminal and intraperitoneal postoperative drainageG Currò, G Piscitelli, C Lazzara, et al.
The Journal of Clinical Endocrinology and Metabolism|January 1, 1989
Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995P Beck-Peccoz, S Mariotti, P J Guillausseau, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 1986
Endocrine, biochemical, and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH), and alpha-subunit: evidence for secretion of TSH with increased bioactivityP Beck-Peccoz, G Piscitelli, S Amr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1997
Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I studyD C Johannessen, T Engan, E Di Salle, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study GroupB Thürlimann, R Paridaens, D Serin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2000
Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trialM Kaufmann, E Bajetta, L Y Dirix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study GroupM Kaufmann, E Bajetta, L Y Dirix, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Clinical Endocrinology|September 1, 1993
The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study GroupJ Webster, G Piscitelli, A Polli, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|June 1, 1986
Evidence for an inhibition of thyroid hormone effects during chronic treatment with amiodaroneP Beck-Peccoz, A Volpi, A P Maggioni, et al.
Hormone Research|January 1, 1988
Treatment of inappropriate secretion of thyrotropin with somatostatin analog SMS 201-995P Beck-Peccoz, G Medri, G Piscitelli, et al.
Il Giornale Di Chirurgia|November 29, 2017
Laparoscopic sleeve gastrectomy for morbid obesity: role of intraluminal and intraperitoneal postoperative drainageG Currò, G Piscitelli, C Lazzara, et al.
The Journal of Clinical Endocrinology and Metabolism|January 1, 1989
Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995P Beck-Peccoz, S Mariotti, P J Guillausseau, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 1986
Endocrine, biochemical, and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH), and alpha-subunit: evidence for secretion of TSH with increased bioactivityP Beck-Peccoz, G Piscitelli, S Amr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1997
Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I studyD C Johannessen, T Engan, E Di Salle, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study GroupB Thürlimann, R Paridaens, D Serin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2000
Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trialM Kaufmann, E Bajetta, L Y Dirix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study GroupM Kaufmann, E Bajetta, L Y Dirix, et al.
Pageof 4